GoodRx Announces Lowest Discounted Cash Price at Retail Pharmacy Locations for neffy® (epinephrine nasal spray)

neffy is available in pharmacies this week and the lowest discounted cash price at retail pharmacies can be found exclusively at GoodRx

neffy is the first and only needle-free treatment for Type I allergic reactions, including anaphylaxis for adults and children who weigh ≥30 kg (66 lbs.)

GoodRx (NASDAQ:GDRX), the leading prescription savings platform in the U.S., today announced it is working with ARS Pharmaceuticals, Inc. ("ARS Pharmaceuticals") to offer the lowest discounted cash price for neffy® in retail pharmacy locations. Available for purchase in-store this week, consumers who have been prescribed neffy can now access a pack of two single-use neffy devices for $199 at more than 70,000 pharmacies nationwide exclusively through GoodRx.

Approved by the Food and Drug Administration in August, neffy is the first needle-free treatment for Type I allergic reactions, including anaphylaxis, offering an innovative alternative to auto-injectors. Unlike traditional methods, neffy delivers epinephrine nasally, avoiding needle injections.

"At GoodRx, we're not just motivated by making essential medications more accessible and affordable, but also by championing innovation within well-established markets," said Dorothy Gemmell, Chief Commercial Officer at GoodRx. "We're committed to offering neffy at a lower price so we can help break down long-standing barriers in anaphylaxis treatment and offer an option that millions of people, especially children and adults who need to carry epinephrine, can use to receive timely and effective treatment."

Allergies and allergy symptoms impact over 100 million Americans annually, with more than 50 million experiencing an allergic reaction each year, underscoring the critical need for accessible treatment. Anaphylaxis, a severe allergic reaction involving the whole body, can induce symptoms such as difficulty breathing, fast heartbeat, hives, nausea, and in severe cases, loss of consciousness, often occurring within seconds or minutes of exposure to an allergen. neffy provides a much-needed option that enhances accessibility and affordability for millions of Americans.

"We're thrilled about neffy's U.S. Food and Drug Administration approval, so people with severe allergies don't have to endure needle-injection of epinephrine, which can be fraught with anxiety and fear, and can carry a device that's small and effective. Through our partnership with GoodRx, we can offer our innovation in retail pharmacies along with patient programs to support its affordability," said Richard Lowenthal, Co-Founder, President, and Chief Executive Officer of ARS Pharmaceuticals. "We're grateful that GoodRx's platform has helped us reach more patients and caregivers to access a needle-free option so they can respond swiftly during a Type 1 allergic reaction."

By partnering with nearly 150 brands across pharmaceutical manufacturers, medical device companies, and OTC medicines, GoodRx directly links savings and patient support programs to high-intent audiences through its platform, enhancing access to more cost-effective treatments across the healthcare industry. The company recently announced an affordability program with Boehringer Ingelheim to provide its Humira® biosimilar (adalimumab) at a low cash price available exclusively on GoodRx. Similarly, the company has partnered with Sanofi to offer its insulin Lantus at just $35.

Consumers can access the savings on neffy at www.goodrx.com/neffy

For Important Safety Information, please see neffy.com and full Patient Information

About GoodRx

GoodRx is the leading prescription savings platform in the U.S. Trusted by more than 25 million consumers and 750,000 healthcare professionals annually, GoodRx provides access to savings and affordability options for generic and brand-name medications at more than 70,000 pharmacies nationwide, as well as comprehensive healthcare research and information. Since 2011, GoodRx has helped consumers save over $75 billion on the cost of their prescriptions.

GoodRx periodically posts information that may be important to investors on its investor relations website at https://investors.goodrx.com. We intend to use our website as a means of disclosing material nonpublic information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors and potential investors are encouraged to consult GoodRx's website regularly for important information, in addition to following GoodRx's press releases, filings with the Securities and Exchange Commission (the "SEC") and public conference calls and webcasts. The information contained on, or that may be accessed through, GoodRx's website is not incorporated by reference into, and is not a part of, this press release.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding anticipated consumer savings and accessibility; the expected benefits and value of our partnership with ARS Pharmaceuticals and GoodRx's other offerings; and our plans, expectations and objectives. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, risks relating to our ability to achieve broad market education and change consumer purchasing habits; changes in medication pricing and pricing structures; our reliance on a limited number of industry participants; and the important factors discussed under the caption "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2023, and our other filings with the SEC. Any such forward-looking statements are based on current expectations, projections and estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240926822763/en/